rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Ovid Therapeutics Inc.

OVID · Nasdaq

Health CareBiotechnologyNot moving yet

OVID stood above a rising 150-day average in 48 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 15.8% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 4
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$59K
Officials’ trades on record
0
Institutions holding
128 (+28)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 48 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$56K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months2
Buyers · sellers0 · 2
WhoDidSharesTraded
Jeffrey A. RonaCBFOsold8,541at $1.4523 Feb 2026filed 2 Mar 2026
Margaret A. AlexanderPresident and CEOsold11,656at $1.4523 Feb 2026filed 2 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders128+28 on the quarter
New · exited45 · 18
Reported value$396.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Jupiter Topco LLCnew · filed 14 Aug 202620,741,234$55.9M+20,741,234
EVENTIDE ASSET MANAGEMENT, LLCadded · filed 14 Aug 202611,812,241$31.8M+1,895,330+19.1%
BlackRock, Inc.added · filed 7 Aug 202610,823,480$29.1M+9,290,197+605.9%
RA CAPITAL MANAGEMENT, L.P.reduced · filed 14 Aug 202610,500,968$28.2M-213,032−2.0%
Affinity Asset Advisors, LLCreduced · filed 13 Aug 202610,144,562$27.3M-491,756−4.6%
STATE STREET CORPadded · filed 7 Aug 20267,900,765$21.3M+7,380,482+1418.6%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20267,760,114$20.9M+2,501,868+47.6%
ADAR1 Capital Management, LLCadded · filed 14 Aug 20267,417,479$20.0M+2,873,366+63.2%
Balyasny Asset Management L.P.added · filed 14 Aug 20266,719,076$18.1M+1,186,003+21.4%
ADAGE CAPITAL PARTNERS GP, L.L.C.unchanged · filed 14 Aug 20266,163,781$16.6M00.0%
31 Mar 2023 – 30 Jun 2026
5188125Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Charles Ross Carter Company insiderChief Financial Officer · last 6 Jul 20260 · 0
Anna Greka Company insiderDirector · last 15 Jun 20260 · 0
Bart Friedman Company insiderDirector · last 7 Apr 20260 · 0
Kevin Joseph Fitzgerald Company insiderDirector · last 7 Apr 20260 · 0
Stelios Papadopoulos Company insiderDirector · last 7 Apr 20260 · 0
Jeremy M. Levin Company insiderExecutive Chairman · last 23 Mar 20265 · 0
Barbara Gayle Duncan Company insiderDirector · last 26 Feb 20260 · 0
Jeffrey A. Rona Company insiderCBFO · last 26 Feb 20260 · 2
Karen Bernstein Company insiderDirector · last 26 Feb 20262 · 0
Margaret A. Alexander Company insiderPresident and CEO · last 26 Feb 20261 · 2
Takeda Pharmaceuticals U.s.a., Inc. Company insider10% owner · last 8 Dec 20250 · 0
Jason Tardio Company insiderChief Operating Officer · last 22 Feb 20240 · 1

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-585%
Free cash flow marginFY 2025 · to 31 Dec 2025-529%
Return on capital employedFY 2025 · to 31 Dec 2025-29.8%
Research spendFY 2025 · to 31 Dec 2025353%
Share count trendFY 2025 · to 16 Mar 20261.3%
Cash and equivalentsFY 2025 · to 31 Dec 2025$13.2M
Free cash flowFY 2025 · to 31 Dec 2025−$38.3M

Analyst forecasts

No analyst forecasts yet.